SARS-COV-2 SEROLOGY REQUEST FORM for Evaluation of Possible Multisystem Inflammatory Syndrome in Children (MIS-C)

SARS-COV-2 SEROLOGY REQUEST FORM for Evaluation of Possible Multisystem Inflammatory Syndrome in Children (MIS-C)

SARS-COV-2 SEROLOGY REQUEST FORM For evaluation of possible Multisystem Inflammatory Syndrome in Children (MIS-C) INSTRUCTIONS • This form is confidential when completed • Are you reuesting serology as part of an evaluation for Multisystem Inflammatory Syndrome in Children (MIS-C) at CC o If YES then page the Medical Microbiologist on call to discuss the case and obtain approval Once approval obtained fill out this form and send by secure email to misccwbcca o If O then page the Medical Microbiologist on call to discuss the case and obtain approval MIS-C Is a legally reportable condition If patient meets case definition criteria the content of this form will be included in case report form at the time of reporting by C Childrens ospital • HEALTHCARE PROVIDER REQUESTING SEROLOGY/PROVIDING CASE INFORMATION Hospital/clinic name: Phone Physician - ext. Number: Name: Fax Email: - ext. Number: Date of serology ame of medial miroiologist request: ase disussed with: YYYY / MM / DD A) CASE PERSONAL INFORMATION Name: Last First Middle Date of Birth: Sex: □ Male □ Female □ Undifferentiated □ Unknown YYYY / MM / DD Health Card Number: Alternate Name(s): Address: Unit # Street # Street Name City Postal Code: Province: Country of Residence (if not Canada): B) INDIGENOUS INFORMATION Do you self-identify as an Indigenous Person? □ Asked, not provided □No □Non-BC Resident □Yes Indigenous Identity: □ Asked, but unknown □ Asked, not provided □ First Nations □ First Nations and Inuit □ First Nations and Métis □ First Nations, Inuit and Métis □Inuit □Inuit and Métis □Métis □ Not asked First Nations Status: □ Asked, but unknown □ Asked, not provided □Non-Status Indian □ Not Asked □ Status Indian Indigenous Organization: _____________________________________ C) COMORBIDITIES / PAST HISTORY Does the case have a chronic disease or comorbidity? □ Yes □ No □ Not assessed If yes, specify 1: specify 2: specify 3: Published Date: 06-Jan-2021 Review Date: 06-Jan-2024 C-05-06-60775 Version date: eemer 2, 2020 Confidential when Completed Page 1 of 3 SARS-COV-2 SEROLOGY REQUEST FORM D) COVID-19 EXPOSURE Was the case in close contact with a laboratory confirmed or probable or epi-linked probable COVID-19 case? □ Yes □ No □ Unknown If yes: First Contact Date or Contact Setting Name PHN Last Contact Date Sustained Contact (e.g., household) Last, First YYYY / MM / DD YYYY / MM / DD □ Sustained contact □ Sustained contact □ Sustained contact E) SIGNS AND SYMPTOMS AT PRESENTATION / / Onset of earliest symptom: YYYY MM DD Presentation Yes No Unknown Not Assessed Fever □ □ □ □ If yes, duration of fever:_____ days Features of hypotension or shock Shock (hypotension, tachycardia, prolonged capillary refill time, pale/mottled skin, cold extremities, or urinary output □ □ □ □ <2 mL/kg/hr) Cutaneous and mucocutaneous Skin rash □ □ □ □ Conjunctivitis (bilateral, non-purulent) □ □ □ □ Oral mucosal inflammation □ □ □ □ Peripheral signs of inflammation (e.g. erythema and edema or peeling of hands and/or feet) □ □ □ □ Gastrointestinal Acute abdominal pain □ □ □ □ Diarrhea □ □ □ □ Vomiting □ □ □ □ Other specify1: _________________________ □ □ □ □ specify2: _________________________ □ □ □ □ specify3 :_________________________ □ □ □ □ specify4: _________________________ □ □ □ □ F) CONSENT TO BE CONTACTED ABOUT IOARESEARCH STUDIES Yes No s the famil willing to e ontated phone or mail aout the CC ioan andor researh studies at CC to improe our understanding of CV1 and other infetiousinflammator onditions of hildhood □ □ Published Date: 06-Jan-2021 Review Date: 06-Jan-2024 C-05-06-60775 Version date: eemer 2, 2020 Confidential when Completed Page 2 of 3 SARS-COV-2 SEROLOGY REQUEST FORM F) DEFINITIONS COV- A person with laboratory confirmation of infection with the virus that causes COVID-19 performed at a community, hospital, or reference Confirmed – lab laboratory (NML or a provincial public health laboratory) running a validated assay. This consists of detection of at least one specific gene target case by a NAAT assay (e.g., real-time PCR or nucleic acid sequencing). COVID-19 A person (who has had a laboratory test) with fever (over 38 degrees Celsius) or new onset of (or exacerbation of chronic) cough AND who meets Probable – lab the COVID-19 exposure criteria and in whom a laboratory diagnosis of COVID-19 is inconclusive. case Visit http://www.bccdc.ca/health-professionals/clinical-resources/case-definitions/covid-19-(novel-coronavirus) forCOVID-19 exposure criteria. COVID-19 A person with fever (over 38 degrees Celsius) or new onset of (or exacerbation of chronic) cough AND either close contact with a confirmed case Probable – epi- of COVID-19 or lived in or worked in a closed facility known to be experiencing an outbreak of COVID-19 (e.g., long-term care facility, prison). linked case Published Date: 06-Jan-2021 Review Date: 06-Jan-2024 C-05-06-60775 Version date: December 2, 2020 Confidential when Completed Page 3 of 3 .

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    3 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us